Lets fight cancer together
Genomate: the right drug.
The first time. Every time.
Learn MoreDuring our lifetime, 1 in 2 people will develop some form of cancer. That’s over 4 billion people and counting.
The targeted therapies that currently exist are focused on only some of the most frequent cancer genes and often fail to work due to the complex, unique molecular background of each tumor.
- Reuters: New U.S. cancer drug prices rise 53% in five years
The genetic cause can be identified in 95% of tumors.*
Each tumor is driven by a unique polygenic alteration signature that includes, on average, 4-5 driver mutations out of millions in 700+ cancer genes. Even with all this information available, 93% of patients don’t currently benefit from targeted therapy due to the combinations of mutations driving their cancer.
It’s time for individualized targeted therapy
Introducing Genomate™, the first clinically validated universal computational reasoning model that can predict response to multiple targeted therapies by analyzing each patient's unique combinations of genetic alterations and biomarkers.
Simplifying genomic complexity
Genomate begins by analyzing the patient's unique genetic profile, examining 100% of their cancer mutations simultaneously. This comprehensive approach allows for a detailed understanding of the molecular characteristics of the disease.
Genomate calculate all possibilities
Leveraging advanced reasoning algorithms, Genomate interprets the genomic data to identify actionable therapy insights. By correlating genetic mutations with treatment response data from a vast database, Genomate predicts the most effective therapies for each patient. This method is the culmination of more than two decades of scientific research and is backed by clinical trial data.
Each patient gets an unique report
Based on the analysis, Genomate generates personalized treatment recommendations tailored to the individual patient. The result is presented as a comprehensive, data-backed report that guides oncologists and patients toward the most suitable treatment, enhancing the efficacy of therapies.
Delivering the promise of precision oncology
Genomate™ delivers the first computational reasoning solution to implement the true promise of precision oncology of N-of-1 therapy based on the genomic profile of the patient’s tumor.
Developed by physicians for physicians
With a team of world-class researchers, scientists, and healthcare professionals, we have invested over two decades in research, development, and innovation to create a solution that redefines the standard of care in cancer treatment. Our vision is to advance the technology to transform clinical decision-making, molecular diagnostics, and drug discovery.
Istvan Petak, MD, PhD
CEO, CSO & Founder
Dr. Istvan Petak is an international expert in precision oncology and molecular pharmacology of targeted therapies with 25+ years of experience. He is the founder and CEO of Genomate Health, Inc. Cambridge, MA, founder and board director of Oncompass Medicine, Budapest, HU, and adjunct professor at the Department of Pharmaceutical Sciences at the University of Illinois at Chicago (UIC). He started his molecular pathology and signal transduction therapy career at Semmelweis University and St. Jude Children's Research Hospital (Memphis, TN). His main achievements are exploring the role of apoptotic pathways in individual drug sensitivity, pioneering molecular companion diagnostics of the EGFR gene in 2003, and implementing NGS (next-generation sequencing) in precision oncology in 2008. He is the lead inventor of a novel computational method, published in 2021, for standardized, personalized treatment recommendations that has won numerous recognitions from organizations, including DIGITALEUROPE and ASCO.
Irving Levy, CPA
Advisor - Finance & Administration
Mr. Levy is an accomplished entrepreneur, financial leader, and philanthropist with a 40-year career. He currently serves as President of Genomate Health, Inc. and Executive Director of the Foundation for Jewish Philanthropies. As a founding member of Exigence Group, a physician practice management start-up, Mr. Levy’s financial expertise led to remarkable growth, culminating in a $120 million expansion and exit in seven years in a sale to TeamHealth, a prominent public company owned by Blackstone Private Equity. Mr. Levy actively invests in early-stage enterprises as a General Partner in Impact Capital LLC, Buffalo Capital Partners LLC, and CPB Holdings Solutions, LLC.Mr. Levy was a Director and Partner of a Top 100 US public accounting firm, specializing in tax, healthcare, and entrepreneurial advisory services.
Mr. Levy’s extensive board involvement showcases his leadership capabilities and commitment to making a positive impact on the community.
Ioana Stupariu, LLM
Chief of Staff & Head of Legal
Ms. Stupariu is a technology regulation expert, with 15 years of experience in project management and operations and academic background in international business law. She founded ReadyTech Consulting, a boutique consultancy focused on providing regulatory, legal & compliance support to SMEs and is now an advisor for multiple technology driven startups in the region. Her professional portfolio also includes being Country Data Protection Officer for a large automotive company (responsible for 8 legal entities and 19.000 employees) and assistant professor of EU and International Law for 400- law student cohorts. Her PhD research at Central European University, Columbia Law School and China University of Political Science and Law allowed her to study applied privacy and technology in depth.
As a project and event manager, she has organized over 100 international events. She founded and coordinated an entrepreneurship social inclusion program for youth with thousands of beneficiaries (YouthBank Romania), and then an international academic network with members in 15 European countries and managed a team of 50 members (Lawyr.it).
Sean Khozin, MD, MPH
Advisor on Medical Affairs & Regulatory Strategy
Dr. Sean Khozin is a globally recognized oncologist, data scientist, and physician-executive with extensive experience in therapeutic development and AI applications in biomedical research. As the founder of Phyusion and Senior Partner at Braven, he focuses on advancing innovations at the nexus of biology, technology, and AI. Previously, he was the CEO of CancerLinQ, the Global Head of Data Strategy at Johnson & Johnson, and a founding member of the US FDA’s Oncology Center of Excellence in addition to serving as the founding executive director of INFORMED, FDA’s first science and technology incubator. Dr. Khozin is the cofounder of the technology company Hello Health and founder of SKMD, a multidisciplinary network of clinics utilizing telemedicine and remote monitoring tools to improve patient outcomes. He is a Research Affiliate at MIT and started his clinical research work at the US National Cancer Institute developing molecular profiling strategies in thoracic malignancies.
Dr. Khozin’s board appointments include the Society for Translational Oncology, Alliance for AI in Healthcare, Digital Medicine Society, and the CEO Roundtable on Cancer’s Life Sciences Council.
In the SHIVA01 clinical trial, patients who received Genomate-recommended targeted therapy had a 4X higher positive response rate than patients who received therapies prescribed by an elite MTB but not recommended by Genomate. Patients treated with Genomate-recommended therapy have a 3X longer progression-free survival.
Nature Precision Oncology (2021)
When used for pediatric tumors, 72% of pediatric cancer cases have been paired with matching targeted treatment when using Genomate. A remarkable 56 out of 72 actionable cases were approved for Genomate-recommended treatments by various international MTBs.
World Journal of Pediatrics (2023)
In treating solid tumors, a 70% higher durable disease control rate (6 months +) was achieved with Genomate-recommended therapies.
ASCO (2023)
Don't just take our word for it – hear from oncologists, healthcare professionals, and patients who have experienced the impact of Genomate™ firsthand.
Through its participation in the Mayo Clinic_Accelerate Program, Genomate™ gained access to invaluable resources, mentorship, and expertise from Mayo Clinic experts, further enhancing its ability to bring innovative solutions to market and transform the landscape of cancer treatment.
Genomate Health Graduates from Mayo Clinic Platform_Accelerate
Genomate™ proudly stands as a founding member and key contributor to the White House-led CancerX initiative. The aim of this public-private partnership is to unite multiple stakeholders and innovators to create a future that's free of the burden of cancer.
Genomate Health is founding member of CancerX
“With the help of Genomate™ we can base our decisions on multiple parameters and rare alterations, making the next step toward the full implementation of the concept of precision oncology. “
Prof. Dr. Christophe Le Tourneau, Head of Phase I Unit. Institut Curie, Paris
Principal investigator of the world’s first randomized clinical trial in precision oncology
"Much has transpired since my diagnosis, and perhaps the most rewarding aspect is that I have welcomed three grandchildren into my life. Now, I can actively participate in the lives of five children as a doting grandmother."
Katalin
Diagnosed with metastatic lung cancer with lymph and brain metastases. One of the first patients to benefit from the method behind Genomate. Symptom-free for over 10 years
.svg)
.svg)